Although RAS/MAPK pathway mutations affecting NRAS, KRAS, and/or PTPN11 are common in de novo or acute myeloid leukemia (AML)-myelodysplasia-related (MR), BRAF variants rarely occur in AML [3]. This evidence concerns the gene KRAS and acute myeloid leukemia.